Diabeloop

Executive Summary

Diabeloop is a French digital health company founded in 2015 that develops automated insulin delivery (AID) systems for Type 1 diabetes management. Its flagship product, DBLG1, integrates therapeutic artificial intelligence to personalize insulin delivery in real time, reducing the cognitive burden on patients. The system combines a continuous glucose monitor (CGM), an insulin pump, and a proprietary algorithm that learns from each patient's glucose patterns. Diabeloop has demonstrated improved time-in-range and reduced hypoglycemia in clinical studies, positioning it as a strong competitor in the rapidly growing AID market. The company's mission to alleviate the mental load of diabetes management resonates with patients and healthcare providers, especially as the global prevalence of Type 1 diabetes rises. With CE marking in Europe and ongoing efforts to expand into new markets, Diabeloop is well placed to capture significant market share. Looking ahead, Diabeloop's growth trajectory depends on regulatory approvals and strategic partnerships. The company is reportedly pursuing FDA clearance for the U.S. market, a major catalyst that could unlock substantial revenue. Additionally, positive data from real-world studies or new clinical trials could strengthen its value proposition. Partnerships with larger diabetes device manufacturers or payers may accelerate adoption. However, the competitive landscape includes established players like Medtronic and Tandem Diabetes, and pricing pressures may impact margins. With a differentiated AI-driven approach and a clear focus on user experience, Diabeloop holds promise for both patients and investors.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for DBLG1 system in the United States60% success
• Q4 2026Positive results from pivotal randomized controlled trial comparing DBLG1 to standard of care75% success
• Q3 2026Strategic partnership with a global diabetes device manufacturer for distribution50% success